drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy; genetically engineered T cells administered IV to deplete CD19+ B-cell compartments.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express an anti‑CD19 chimeric antigen receptor and, after IV infusion, bind CD19 on B‑lineage cells (naive and memory B cells and plasmablasts). CAR engagement activates the T cells to kill targets via perforin/granzyme and cytokine‑mediated cytotoxicity, depleting CD19+ B cells and reducing autoantibody production and B cell–mediated antigen presentation/co‑stimulation.
drug_name
RD06-04
nct_id_drug_ref
NCT06549296